These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 18060404)

  • 1. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses.
    Harrop R; Drury N; Shingler W; Chikoti P; Redchenko I; Carroll MW; Kingsman SM; Naylor S; Griffiths R; Steven N; Hawkins RE
    Cancer Immunol Immunother; 2008 Jul; 57(7):977-86. PubMed ID: 18060404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses.
    Harrop R; Drury N; Shingler W; Chikoti P; Redchenko I; Carroll MW; Kingsman SM; Naylor S; Melcher A; Nicholls J; Wassan H; Habib N; Anthoney A
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4487-94. PubMed ID: 17671134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial.
    Harrop R; Connolly N; Redchenko I; Valle J; Saunders M; Ryan MG; Myers KA; Drury N; Kingsman SM; Hawkins RE; Carroll MW
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3416-24. PubMed ID: 16740766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TroVax in colorectal cancer.
    Rowe J; Cen P
    Hum Vaccin Immunother; 2014; 10(11):3196-200. PubMed ID: 25483641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial.
    Amato RJ; Shingler W; Naylor S; Jac J; Willis J; Saxena S; Hernandez-McClain J; Harrop R
    Clin Cancer Res; 2008 Nov; 14(22):7504-10. PubMed ID: 19010868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial.
    Amato RJ; Shingler W; Goonewardena M; de Belin J; Naylor S; Jac J; Willis J; Saxena S; Hernandez-McClain J; Harrop R
    J Immunother; 2009 Sep; 32(7):765-72. PubMed ID: 19561532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial.
    Amato RJ; Drury N; Naylor S; Jac J; Saxena S; Cao A; Hernandez-McClain J; Harrop R
    J Immunother; 2008; 31(6):577-85. PubMed ID: 18528296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial.
    Harrop R; Chu F; Gabrail N; Srinivas S; Blount D; Ferrari A
    Cancer Immunol Immunother; 2013 Sep; 62(9):1511-20. PubMed ID: 23877659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha.
    Hawkins RE; Macdermott C; Shablak A; Hamer C; Thistlethwaite F; Drury NL; Chikoti P; Shingler W; Naylor S; Harrop R
    J Immunother; 2009 May; 32(4):424-9. PubMed ID: 19342962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients.
    Harrop R; Shingler W; Kelleher M; de Belin J; Treasure P
    J Immunother; 2010; 33(9):999-1005. PubMed ID: 20948436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Modified Vaccinia Ankara-5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Scurr M; Pembroke T; Bloom A; Roberts D; Thomson A; Smart K; Bridgeman H; Adams R; Brewster A; Jones R; Gwynne S; Blount D; Harrop R; Wright M; Hills R; Gallimore A; Godkin A
    JAMA Oncol; 2017 Oct; 3(10):e172579. PubMed ID: 28880972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.
    Amato RJ
    Expert Opin Biol Ther; 2010 Feb; 10(2):281-7. PubMed ID: 20088718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer.
    Weihrauch MR; Ansén S; Jurkiewicz E; Geisen C; Xia Z; Anderson KS; Gracien E; Schmidt M; Wittig B; Diehl V; Wolf J; Bohlen H; Nadler LM
    Clin Cancer Res; 2005 Aug; 11(16):5993-6001. PubMed ID: 16115944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4).
    Elkord E; Dangoor A; Burt DJ; Southgate TD; Daayana S; Harrop R; Drijfhout JW; Sherlock D; Hawkins RE; Stern PL
    Cancer Immunol Immunother; 2009 Oct; 58(10):1657-67. PubMed ID: 19221742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
    Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
    Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
    Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
    Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
    Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer.
    Kaufman HL; Lenz HJ; Marshall J; Singh D; Garett C; Cripps C; Moore M; von Mehren M; Dalfen R; Heim WJ; Conry RM; Urba WJ; Benson AB; Yu M; Caterini J; Kim-Schulze S; Debenedette M; Salha D; Vogel T; Elias I; Berinstein NL
    Clin Cancer Res; 2008 Aug; 14(15):4843-9. PubMed ID: 18676757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer.
    Van Cutsem E; Pozzo C; Starkhammar H; Dirix L; Terzoli E; Cognetti F; Humblet Y; Garufi C; Filez L; Gruia G; Cote C; Barone C
    Ann Oncol; 1998 Nov; 9(11):1199-204. PubMed ID: 9862050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5T4-modified vaccinia ankara: progress in tumor-associated antigen-based immunotherapy.
    Amato RJ
    Expert Opin Biol Ther; 2007 Sep; 7(9):1463-9. PubMed ID: 17727334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.